GLP-1 - Research Site - Older Adult

Trial Radar AI Trial Candidate or Patient Patient Caregiver Healthcare Pro Biotech Pro Biotech Investor Researcher Other
	Showing clinical trials matching location: Research Site. I can help you find nearby clinical trials and understand health conditions and treatments.

Study Title	Status
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (EXCEED) NCT05663515	Recruiting
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM (VESPER-2) NCT06897202	Active, not recruiting
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight (VESPER-1) NCT06712836	Active, not recruiting
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants NCT06737042	Not yet recruiting
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH NCT06410924	Active, not recruiting
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist (ARAY) NCT06851858	Active, not recruiting
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight (VESPER-3) NCT06973720	Active, not recruiting
Aleniglipron Phase 2 Body Composition Study NCT07169942	Active, not recruiting
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes NCT06924320	Recruiting
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (ACCESS II) NCT06703021	Active, not recruiting
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (ACCESS) NCT06693843	Active, not recruiting
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity NCT06373146	Active, not recruiting
Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus NCT06700538	Recruiting
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes NCT05822544	Recruiting
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO) NCT06588283	Active, not recruiting
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA) NCT06588296	Active, not recruiting
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY) NCT05433584	Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) NCT05556512	Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) NCT06914895	Active, not recruiting
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2) NCT06962280	Active, not recruiting